ES487019A1 - Un procedimiento para la preparacion de sales de resinas de intercambio anionico activadas y atoxicas con acidos fenoxi-propionicos - Google Patents

Un procedimiento para la preparacion de sales de resinas de intercambio anionico activadas y atoxicas con acidos fenoxi-propionicos

Info

Publication number
ES487019A1
ES487019A1 ES487019A ES487019A ES487019A1 ES 487019 A1 ES487019 A1 ES 487019A1 ES 487019 A ES487019 A ES 487019A ES 487019 A ES487019 A ES 487019A ES 487019 A1 ES487019 A1 ES 487019A1
Authority
ES
Spain
Prior art keywords
salts
chlorobenzoyl
group
phenoxy
resins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES487019A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Farmaceutici SpA
Original Assignee
Alfa Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Farmaceutici SpA filed Critical Alfa Farmaceutici SpA
Publication of ES487019A1 publication Critical patent/ES487019A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
    • C08B15/05—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur
    • C08B15/06—Derivatives containing elements other than carbon, hydrogen, oxygen, halogens or sulfur containing nitrogen, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Phenolic Resins Or Amino Resins (AREA)

Abstract

UN procedimiento para la preparación de sales de resinas de intercambio aniónico activadas y atóxicas con ácidos fenoxipropiónicos , aptas para rebajar altos contenidos de colesterol y triglicéridos en la sangre, en donde el grado de salificación varia de 0,7 a 100% de la capacidad de intercambio de las resinas eligiéndose las resinas entre el grupo de las a) resinas inertes a las enzimas digestivas con un esqueleto polimérico estirénico o acrílico reticulado, un peso molecular superior a 1000 y grupos amínicos ionizables, b) resinas modificadas por grupos amínicos libres o sustituidos con esqueleto celulósico reticulado. C) resinas modificadas reticuladas por medio de grupos amínicos libres o sustituidos con un esqueleto polisacárido, y teniendo los ácidos fenoxiporpiónicos la fórmula general. **fórmula** en donde R Representa cloro, p-clorobenzoilo, p-bromobenzoilo o p-fluorobenzoilo, R representa hidrógeno , alquilo C1-C3 o hidroxi-alquilo (C1-C3) W puede ser un grupo hidroxílico o un radical elegido entre -N (R''`'')-CH(R''`)-(CH2)n- COOH y -O-CH2-COOH en donde n representa un número entero de 0 a 5, R''`'' representa hidrógeno, bencilo, fenilo, fenilo hidroxi-sustituido, alquilo (C1-C4), alcoxilo (C1-C4) o hidroxi -alquilo (C1-C4), R''`'' representa hidrógeno o alquilo (c1-4) caracterizado porque comprende activar la resina seleccionada mediante lavado por tres veces con ácido clorhídrico 0,1 N , agua destilada e hidróxido sódico, 0,1N, lavar de nuevo la resina con ácido clorhídrico, 0,1 N tratar en una columna cromatográfica la resina así activada, con una proporción molar de un ácido de la fórmula general I disuelto en una proporción equivalente de hidróxido sódico y N y eluir con aguas destilada hasta que desaparezcan los aniones en los eluatos.
ES487019A 1978-12-21 1979-12-18 Un procedimiento para la preparacion de sales de resinas de intercambio anionico activadas y atoxicas con acidos fenoxi-propionicos Expired ES487019A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT03631/78A IT1106718B (it) 1978-12-21 1978-12-21 Composizioni a base di resine anioniche salificate farmacologicamente attive

Publications (1)

Publication Number Publication Date
ES487019A1 true ES487019A1 (es) 1980-10-01

Family

ID=11110905

Family Applications (1)

Application Number Title Priority Date Filing Date
ES487019A Expired ES487019A1 (es) 1978-12-21 1979-12-18 Un procedimiento para la preparacion de sales de resinas de intercambio anionico activadas y atoxicas con acidos fenoxi-propionicos

Country Status (11)

Country Link
US (1) US4340585A (es)
EP (1) EP0012804B2 (es)
JP (1) JPS55115403A (es)
AT (1) ATE502T1 (es)
DE (1) DE2961714D1 (es)
DK (1) DK159660C (es)
ES (1) ES487019A1 (es)
GR (1) GR72734B (es)
IT (1) IT1106718B (es)
NO (1) NO794225L (es)
YU (1) YU313079A (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393145A (en) * 1979-05-01 1983-07-12 Etablissement Texcontor Anionic ion exchange resins with cholesterol-decreasing properties
CH655507B (es) * 1983-01-12 1986-04-30
US4790991A (en) * 1985-02-05 1988-12-13 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4747881A (en) * 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4851392A (en) * 1985-02-05 1989-07-25 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4818539A (en) * 1985-02-05 1989-04-04 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4843098A (en) * 1985-02-05 1989-06-27 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4877775A (en) * 1986-06-16 1989-10-31 E. I. Du Pont De Nemours And Company Polymeric aminosaccharides as antihypercholesterolemic agents
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5498678A (en) * 1992-12-21 1996-03-12 Rohm And Haas Company Suspension polymerization process for water-soluble monomers
US5451397A (en) * 1992-12-21 1995-09-19 Rohm And Haas Company Bile acid sequestrant
US5607669A (en) * 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US5618530A (en) * 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
US5900475A (en) * 1994-06-10 1999-05-04 Geltex Pharmaceuticals, Inc. Hydrophobic sequestrant for cholesterol depletion
US5929184A (en) * 1993-06-02 1999-07-27 Geltex Pharmaceuticals, Inc. Hydrophilic nonamine-containing and amine-containing copolymers and their use as bile acid sequestrants
US5703188A (en) * 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5624963A (en) * 1993-06-02 1997-04-29 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US6129910A (en) * 1993-06-02 2000-10-10 Geltex Pharmaceuticals, Inc. Water-insoluble noncrosslinked bile acid sequestrants
TW474813B (en) * 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
US5753262A (en) * 1995-06-07 1998-05-19 Aronex Pharmaceuticals, Inc. Cationic lipid acid salt of 3beta N- (N', N'-dimethylaminoethane) - carbamoyl!cholestrol and halogenated solvent-free preliposomal lyophilate thereof
US6203785B1 (en) 1996-12-30 2001-03-20 Geltex Pharmaceuticals, Inc. Poly(diallylamine)-based bile acid sequestrants
US6423754B1 (en) * 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
EP1572190B1 (en) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
CA2815698C (en) 2010-11-08 2019-04-30 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
RS57778B1 (sr) 2010-11-08 2018-12-31 Albireo Ab Inhibitori crevnog transportera žučne kiseline (ibat) za lečenje bolesti jetre
KR20190135545A (ko) 2011-10-28 2019-12-06 루메나 파마수티컬즈, 인코포레이티드 고담혈증 및 담즙 정체성 간 질환 치료용 담즙산 재순환 억제제
MX369466B (es) 2011-10-28 2019-11-08 Lumena Pharmaceuticals Inc Inhibidores de la recirculación de ácidos biliares para el tratamiento de enfermedades hepáticas colestásicas pediátricas.
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
JP2016514684A (ja) 2013-03-15 2016-05-23 ルメナ ファーマシューティカルズ エルエルシー 原発性硬化性胆管炎および炎症性腸疾患の処置のための胆汁酸再循環阻害剤
KR20210137046A (ko) 2019-02-12 2021-11-17 미룸 파마슈티컬스, 인크. 담즙정체의 치료 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB857194A (en) * 1957-07-05 1960-12-29 Clinical Products Ltd Therapeutic agents comprising ion-exchange resins
BE580490A (fr) 1958-07-15 1960-01-08 Merck & Co Inc Compositions et procédés pour abaisser la teneur en cholestérol du sang
FR4933M (es) * 1964-09-17 1967-03-28
NL7017227A (es) 1969-12-27 1971-06-29
GB1348642A (en) * 1970-10-15 1974-03-20 Howard A N Hypocholesterolaemic compositions
US4027009A (en) * 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol

Also Published As

Publication number Publication date
GR72734B (es) 1983-12-01
DK159660C (da) 1991-04-08
IT7803631A0 (it) 1978-12-21
EP0012804B2 (de) 1987-03-04
YU313079A (en) 1983-02-28
JPS55115403A (en) 1980-09-05
ATE502T1 (de) 1982-01-15
EP0012804B1 (de) 1981-12-30
US4340585A (en) 1982-07-20
DK548279A (da) 1980-06-22
IT1106718B (it) 1985-11-18
DK159660B (da) 1990-11-12
JPS6327362B2 (es) 1988-06-02
DE2961714D1 (en) 1982-02-18
EP0012804A1 (de) 1980-07-09
NO794225L (no) 1980-06-24

Similar Documents

Publication Publication Date Title
ES487019A1 (es) Un procedimiento para la preparacion de sales de resinas de intercambio anionico activadas y atoxicas con acidos fenoxi-propionicos
DK0764177T3 (da) Præparat, der indeholder tværbunden polymer, til fjernelse af galdesyresalte fra en patient
GR3031583T3 (en) Cholesterol level depressant.
NO308792B1 (no) Derivater av valproinsyre og 2-valproensyreamider, farmasøytisk sammensetning derav og deres anvendelse for fremstilling av et farmasøytisk preparat
GB2255339A (en) Peptidyl derivatives
LU88670I2 (fr) Fluvastatine eventuellement sous forme de sel par exemple sel de sodium
ES8401466A1 (es) Procedimiento para la obtencion de derivados de piridina.
ATE32512T1 (de) Piperazinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES8504690A1 (es) Un procedimiento para preparar una n-(4-(3-aminopropil)-aminobutil)-2-(acido w-guanidino-graso-amido)-2-alcoxietanamida
ES8701228A1 (es) Un metodo para producir una propioxantina
ES482002A1 (es) Procedimiento para la preparacion de nuevos derivados 5-fe- nilpirazolicos.
SE7703901L (sv) Polymer
ES8308543A1 (es) "procedimiento para la preparacion de nuevas 2-fenil-2-(piridiloxi)-etilaminas sustituidas".
ES8106289A1 (es) Procedimiento de preparacion de nuevos derivados del a-fe- nil-2-pirrolidin-metanol
ES465606A1 (es) Procedimiento de preparacion de nuevos derivados de hexahi- dro-1,2,3,3a,4,5-cantina.
ES488387A1 (es) Procedimiento de preparacion de derivados condensados de pi-rrolidina
ES8103740A1 (es) Procedimiento para la obtencion de nuevos derivados de la piperacina metanimina
ATE40948T1 (de) Pyridylalkylnitratverbindung, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzung.
JPS56150017A (en) Cholesteril lowering agent
IE813110L (en) N-substituted iminodiacetic acids.
AU543289B2 (en) 3-thiovinylcephalosporins
ES8506756A1 (es) Procedimiento para preparar derivados de afidicolina.
ES8307253A1 (es) "procedimiento para la preparacion de nuevos derivados dioxazabiciclicos".
ES8200658A1 (es) Procedimiento para la preparacion de sales de alcohileter- isotiuronio
GB1475241A (en) Benzodiazocine derivatives and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970303